Vitamin D Receptor As A Marker of Prognosis In Oesophageal Adenocarcinoma: A Prospective Cohort Study
AuthorsS McCain, J Trainor, DT McManus, ÚC McMenamin, S McQuaid, V Bingham, JA James, M Salto-Tellez, RC Turkington, HG Coleman
Departments / InstitutionsCentre for public health ICS-B Building, RVH Site, Grosvenor Road, Belfast, BT12 6BJ,
Publication DateAutumn 2018
Oesophageal cancer causes 400,000 deaths worldwide each year and ranks as the sixth most common cause of cancer mortality. 5-year survival rates range between 10% and 18%. In addition to early detection initiatives, there is a need to identify actionable, prognostic biomarkers to help predict patient outcome and also to identify novel therapeutic targets.
Vitamin D receptor (VDR) expression has been associated with survival in several cancer sites. This study aims to evaluate the association between VDR expression and prognosis in oesophageal adenocarcinoma patients.
Oesophageal adenocarcinoma specimens and clinical data were collected from 130 patients treated with neo-adjuvant chemotherapy prior to surgical resection at the Northern Ireland Cancer Centre between 2004 and 2012. Tissue microarrays were created and immunohistochemical staining for VDR was performed on triplicate tumour cores from each resection specimen. Cox proportional hazards models were applied to evaluate associations between VDR, according to tertiles of expression, and survival outcomes.
During a median of 2.5 (maximum 9) years of follow-up, 75 patients died. In analysis adjusted for confounders, higher VDR expression was associated with an improved overall survival (HR 0.49 95% CI 0.25-0.96) and disease-specific survival (HR 0.50 95% CI 0.26-0.99), when comparing the highest with the lowest tertile of expression. These associations were strongest in sensitivity analysis restricted to junctional tumours
This study is the first to demonstrate that patients with higher VDR expression in oesophageal adenocarcinoma have a more favourable prognosis. Further work is needed to validate these findings, and to define the role of VDR in the aetiology, progression and management of oesophageal adenocarcinoma.
Event takes place on September 10, 2019 until September 11, 2019
Download our latest Documents